CURE Pharmaceutical
With a name like this, you'd better believe they have big dreams. And those dreams involve marijuana and the little-blue-pill-whose-name-starts-with-V-but-if-we-drop-that-name-this-email-will-get-flagged-as-spam.
Sounds like a fun night, but those aren't cures, just treatments. Typical.
Kyorin
Their pipeline page would have you know that: All of the products we offer carry with them our wish for a "smiley society."
Translation error? Maybe, but we prefer to believe this is just an upbeat-as-hell place to work.
Nihon Pharmaceutical
Then we have Nihon Pharmaceutical whose home page states they are: Continuing to protect irreplaceable "Lives".
Not sure what the quotes around Lives is meant to indicate. Maybe they only have drugs for robots.
Kinaset Therapeutics
New company launched in Boston this week with a cool $40M. Their sole asset is a previously developed molecule they acquired which was formerly known as VR588. Kinaset decided to re-name it KN-002. Look at those sly devils acting like there was ever a KN-001. Lies!
Hopefully all you eosinophilic and non-eosinophilic severe asthma patients out there will get some good news on KN-0021 in a few years.
ALR Technologies
On their most recent 10-Q quarterly report, these guys show $708 in assets despite having a market capitalization of $34M. (They had $596 in assets same time last year, so, hey, up 19%!)
Lines of credit seem to be funding the entire operation. They also appear to be paying 1% per month on a lot of their debt. Seems like a ridiculous rate...ohhhhh wait a minute. There it is. The CEO and his wife have loaned the company $23M of their personal fortune at 1% interest per month.
Milking a cool $2.75M off the company each year in addition to the $240k salary? No conflict of interest to see here. No way would the CEO prioritize paying himself back over moving the business forward.
Maybe an app that pretty much just send texts to your doctor isn't the money spinner they had hoped.